EAN 2026 | NfL and GFAP in MS: towards biomarker-guided precision medicine
Maximilian Einsiedler, MD, University Hospital Basel, Basel, Switzerland, discusses the potential role of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in contributing to biomarker-guided precision medicine for multiple sclerosis (MS). Dr Einsiedler explains how these biomarkers could complement MRI and clinical assessment to monitor disease activity, predict progression, and support more personalized treatment decisions. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s a bit of two separate questions because for neurofilament light chain there are already now some recommendations that can be applied and it’s more and more used already worldwide and I think it should be used at diagnosis and then if possible at regular intervals to assess the current state of inflammatory disease activity and to assess the potential response to DMTs, to treatments...
It’s a bit of two separate questions because for neurofilament light chain there are already now some recommendations that can be applied and it’s more and more used already worldwide and I think it should be used at diagnosis and then if possible at regular intervals to assess the current state of inflammatory disease activity and to assess the potential response to DMTs, to treatments. For GFAP, I think now with this study, we can show that even in large settings, this seems to provide big information on future progression risk, but the exact implementation in the clinic is a bit less clear but I would personally say that it provides very useful information and so I would see it in addition to MRI information to clinical information as an additional parameter to assess the patient’s state regarding the risk of progression and this can then help to assess the correct treatment choice, for example.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
